Vanillylmandelic acid
(Synonyms: 香草扁桃酸；3-甲氧基-4-羟基扁桃酸) 目录号 : GC61438
Vanillylmandelic acid (VMA) is a chemical intermediate in the synthesis of artificial vanilla flavorings and is an end-stage metabolite of the catecholamines
Cas No.:55-10-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Vanillylmandelic acid (VMA) is a chemical intermediate in the synthesis of artificial vanilla flavorings and is an end-stage metabolite of the catecholamines
| Cas No. | 55-10-7 | SDF | |
| 别名 | 香草扁桃酸；3-甲氧基-4-羟基扁桃酸 | ||
| Canonical SMILES | O=C(O)C(O)C1=CC=C(O)C(OC)=C1 | ||
| 分子式 | C9H10O5 | 分子量 | 198.17 |
| 溶解度 | DMSO: 250 mg/mL (1261.54 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.0462 mL | 25.2309 mL | 50.4617 mL |
| 5 mM | 1.0092 mL | 5.0462 mL | 10.0923 mL |
| 10 mM | 0.5046 mL | 2.5231 mL | 5.0462 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Urinary Vanillylmandelic acid:creatinine ratio in dogs with pheochromocytoma
Domest Anim Endocrinol 2021 Jan;74:106559.PMID:32980593DOI:10.1016/j.domaniend.2020.106559.
Pheochromocytoma diagnosis in dogs is challenging because biochemical tests are not always available. In humans, urinary Vanillylmandelic acid (VMA) is part of a pheochromocytoma biochemical diagnostic profile, whereas its diagnostic accuracy is currently unknown in dogs with pheochromocytoma. Prospectively, VMA was determined by HPLC and expressed as the ratio with respect to urinary creatinine (VMA:C). The diagnostic accuracy of the VMA:C ratio was evaluated by analyzing the receiver operating characteristic (ROC) curve in 10 healthy dogs, 8 dogs with pituitary-dependent hypercortisolism, 8 dogs with adrenal-dependent hypercortisolism, and 7 dogs with pheochromocytoma. The pheochromocytoma diagnosis was confirmed by histology and immunohistochemistry in all tumors. The VMA:C ratio was significantly higher in dogs with pheochromocytoma (158 [53.4 to 230.8] × 10-3) than in dogs with adrenal-dependent hypercortisolism (48.1 [24.3 to 144.9] × 10-3; P < 0.05), dogs with pituitary-dependent hypercortisolism (37.5 [32 to 47.1] × 10-3; P < 0.001), and healthy dogs (33.8 [13.3 to 87.9] × 10-3; P < 0.001). When using a VMA:C ratio >58.2 × 10-3 for pheochromocytoma diagnosis, a sensitivity of 85.7% and a specificity of 88.4% were obtained. Nevertheless, when using a cut-off ratio of 4 times the median VMA:C ratio determined in healthy dogs, there was no overlap (100% specificity). The area under the ROC curve indicated that the VMA:C ratio test could be used to discriminate between dogs with and without pheochromocytoma, what leads to the conclusion that it is useful for pheochromocytoma diagnosis in dogs.
Quantitation of Neuroblastoma Markers Homovanillic Acid (HVA) and Vanillylmandelic acid (VMA) in Urine by Gas Chromatography-Mass Spectrometry (GC/MS)
Methods Mol Biol 2022;2546:185-194.PMID:36127589DOI:10.1007/978-1-0716-2565-1_17.
Neuroblastoma and other neural crest tumors can be characterized by the increased production and excretion of catecholamines and their metabolites. Homovanillic acid (HVA) and Vanillylmandelic acid (VMA) are important catecholamine metabolites that can be measured to provide relatively rapid laboratory diagnosis and clinical follow-up of neuroblastoma. We present a procedure to quantify HVA and VMA in urine samples which have been diluted to a creatinine concentration of 2 mg/dL. Diluted samples are spiked with deuterated internal standards, acidified, and extracted with an organic solvent. A bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% trimethylchlorosilane (TMCS) and pyridine mixture is added to the dried extract to create trimethylsilyl derivatives of HVA and VMA. The derivatized compounds are measured using gas chromatography-mass spectrometry (GC/MS).
A Simple, Fast, and Reliable LC-MS/MS Method for the Measurement of Homovanillic Acid and Vanillylmandelic acid in Urine Specimens
Methods Mol Biol 2022;2546:175-183.PMID:36127588DOI:10.1007/978-1-0716-2565-1_16.
Homovanillic acid (HVA) and Vanillylmandelic acid (VMA) are catecholamine metabolites used in the diagnostic workup of neuroendocrine tumors. Here we describe a simple dilute-and-shoot method for simultaneously quantitating HVA and VMA in human urine specimens. The method employs analyte separation on a reverse-phase liquid chromatography column followed by detection using electrospray ionization triple quadrupole mass spectrometry (ESI-MS/MS), wherein qualifier and quantifier ion transitions are monitored. This is a simple and fast analytical method with an injection-to-injection time of 4 min.
Cardiovascular effects of Vanillylmandelic acid in rats
Eur J Pharmacol 2013 Mar 5;703(1-3):46-52.PMID:23399766DOI:10.1016/j.ejphar.2013.01.044.
The main catecholamine end-metabolites have been considered biologically inactive, but accumulated evidence indicates a variety of pharmacological actions after exogenous administration. We examined the dose-related haemodynamic effects of Vanillylmandelic acid in the in vivo rat-model. One hundred and sixteen Wistar rats (250 ± 20 g) were studied under continuous electrocardiographic monitoring; invasive blood pressure was recorded for 60 min through a catheter in the right common carotid artery. Measurements were performed at baseline and after Vanillylmandelic acid (1, 10, 100mg/kg) and homovanillic acid (10mg/kg) intra-arterial administration. To examine the underlying mechanisms, the haemodynamic effects were compared with those (a) after trimetazidine administration, which has similar structure due to a tri-methylated phenolic ring; (b) after epinephrine and isoprenaline administration following Vanillylmandelic acid pretreatment; (c) after Vanillylmandelic acid administration post-bilateral vagotomy. Vanillylmandelic acid, homovanillic acid and (to a lesser extent) trimetazidine decreased heart rate and mean arterial blood pressure. This effect was blunted in vagotomized animals. Comparable effects were noted in heart rate and blood pressure after adrenaline and isoprenaline infusion, with and without vanillylmandelic acid-pretreatment. In conclusion, Vanillylmandelic acid administration decreases heart rate dose-dependently, mediated by increased vagal tone, without α- or β-adrenergic-receptor blocking effects. The pharmacological properties of compounds with a mono- and tri-methylated phenolic ring merit further investigation.
Quantification of Vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method
Clin Chem Lab Med 2018 Aug 28;56(9):1533-1541.PMID:29708876DOI:10.1515/cclm-2017-1120.
Background: Urinary Vanillylmandelic acid (VMA) and homovanillic acid (HVA) are biomarkers for the diagnosis and follow-up of neuroblastoma, whereas urinary 5-hydroxyindoleacetic acid (5-HIAA) is used to assess a carcinoid tumor. These analytes are conventionally analyzed in a single run by chromatography (LC) coupled with electrochemical detection (LC-ECD) using commercial kits. A rapid dilute-and-shoot LC tandem mass spectrometry (LC-MS/MS) assay was validated in order to replace the LC-ECD method and therefore improve analytical specificity and throughput. Methods: Sample preparation was carried out by dilution of the urine sample with a solution containing the deuterated internal standards. The separation was achieved on an ultra-high pressure LC system with MS detection using a triple quadrupole mass spectrometer. The method was validated according to the current EMA and FDA guidelines. Results: The full chromatographic run was achieved in 8 min. The method validation showed excellent linearity (r2>0.999 for all three analytes), precision (CV <15%), negligible matrix effect (recoveries >90%), low carryover (<1%) and LLOQ of 0.25, 0.4 and 0.4 μM for VMA, HVA and 5-HIAA, respectively. Deming fits and Bland-Altman analyses showed no significant differences between the values obtained between the two assays. Conclusions: The LC-MS/MS method proposed in this study is fast and robust, and the simple sample preparation saves time and avoids the additional costs of dedicated kits used for the LC-ECD assays by switching to LC-MS/MS. Additionally, the near-perfect correlation observed herein between both assays allows the previously established reference ranges to be maintained.